Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Keep up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Follow the steps in this form to help you develop and implement an effective healthcare equity plan for your lab.
Recent case shows that fraud and kickback schemes involving CGx testing continue to be on the federal enforcement radar.
As of January 1, 2023, your lab may need to develop and implement a full-blown health equity plan to maintain its Joint Commission accreditation.
After the price transparency rules took effect in January 2021, CMS finally issued the first penalties for violations.
CMS has instructed its MACs to recognize eight new CLIA-waived complexity tests for which labs will be allowed to bill, effective Oct. 1.
Mark Schena was convicted of swindling investors and running a $77 million kickback scheme involving COVID-19 and allergy tests.
Biden administration blames the decision on Congress’ failure to provide the additional funding necessary to keep the program going.
It remains far from clear whether the new surprise billing rule goes far enough to fix the problem of insurers having too much power in disputes.
In a move to expand access to lab testing for monkeypox, HHS has authorized the FDA to issue EUAs for in vitro diagnostic tests for the virus.
On August 21, the FDA proposed new guidelines on charging for investigational drugs; here are the key highlights.